A Food and Drug Administration (FDA) advisory committee has voted 11 to 2 against a recommendation that the agency approve a long-studied antiarrhythmic agent for cardioversion of recent-onset atrial ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback